Biogen ends trial of Alzheimer's drug
Thursday, March 21, 2019 - 10:00
in Health & Medicine
Biotechnology giant Biogen said it was ending its Phase 3 trial of an Alzheimer's disease drug because it was not likely to "meet their primary endpoint."